Abstracts tagged "Systemic sclerosis"

Abstract Number: 718 • 2019 ACR/ARP Annual Meeting
Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions
Håvard Fretheim¹, Øyvind Midtvedt ², Torhild Garen ², Arne Kristian Andreassen ², Einar Gude ², Øyvind Molberg ³ and Anna Maria Hoffmann-Vold ⁴, ¹Oslo University Hospital, Oslo, ²Oslo University Hospital, Oslo, Norway, ³University Hospital Oslo, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Pre-capillary pulmonary hypertension (PH) is a feared complication in patients with systemic sclerosis (SSc) and is associated with high mortality despite new treatment options.…
Abstract Number: 864 • 2019 ACR/ARP Annual Meeting
Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Robert Spiera ¹, Dana Orange ², Cynthia Magro ³, Yaxia Zhang ⁴, Jackie Finik ⁵ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Weill Cornell Medicine, New York, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The Combined Response Index in Systemic Sclerosis (CRISS) is a composite outcome measure provisionally endorsed by the American College of Rheumatology for use in…
Abstract Number: 1063 • 2019 ACR/ARP Annual Meeting
Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
David Fox¹, Michael Whitfield ², Veronica Berrocal ³, Steven K. Lundy ⁴, Phillip Campbell ⁵, Stephanie Rasmussen ⁵, Ray Ohara ⁶, Alexander Stinson ⁶, Evan Wiewiora ⁷, Cathie Spino ⁷, Erica Bush ⁸, Daniel Furst ⁹, Shiv Pillai ¹⁰ and Dinesh Khanna ¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI, ²Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴TBD, Seattle, WA, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁶Washington University, St. Louis, MO, ⁷Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, ⁸Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁹University of California at Los Angeles, Los Angeles, CA, ¹⁰Ragon Institude of MGH, MIT and Harvard, Charlestown, MA, ¹¹Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor
Background/Purpose: Background: In a randomized controlled trial of abatacept in early diffuse systemic sclerosis (Khanna D, et al ACR 2018), we observed early clinical flares…
Abstract Number: 1648 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Boyang Zheng¹, Mianbo Wang ², Marvin Fritzler ³, May Choi ³, Murray Baron ⁴ and Marie Hudson ⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Jewish General Hospital, McGill University, Montreal, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is frequent manifestation and a leading cause of mortality in systemic sclerosis (SSc). Some SSc-related autoantibodies (aAbs), especially anti-topoisomerase I…
Abstract Number: 2588 • 2019 ACR/ARP Annual Meeting
Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations
Amélie Leurs ¹, Sylvain Dubucquoi ¹, François Machuron ¹, Maité Balden ¹, Florence Renaud ¹, Stéphanie Rogeau ¹, Benjamin Lopez ², Marc LAMBERT ³, Sandrine Morell-Dubois ⁴, Hélène Maillard ⁴, Hélène Behal ¹, Eric Hachulla ⁵, David Launay ¹ and Vincent Sobanski¹, ¹CHU Lille, Lille, France, ²Institute of Immunology, CHU Lille, University of Lille, Lille, France, ³Lille University Hospital, Lille, France, ⁴Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed…
Abstract Number: 2609 • 2019 ACR/ARP Annual Meeting
Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy
Victoria Flower¹, Shaney Barratt ², Darren Hart ³, Amanda Mackenzie ⁴, Jacqueline Shipley ³, Stephen Ward ⁴ and John Pauling ¹, ¹Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ²North Bristol NHS Trust, Bristol, England, United Kingdom, ³Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ⁴Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, England, United Kingdom
Background/Purpose: The anti-angiogenic isoform of Vascular Endothelial Growth Factor-A (VEGF-A165b) has been implicated in Systemic sclerosis (SSc) vasculopathy. High frequency ultrasound (HFUS) is a novel…
Abstract Number: 719 • 2019 ACR/ARP Annual Meeting
Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth
Hanyan Zou¹, Giada De Palma ², Premysl Bercik ², Elena Verdu ², Karen Beattie ² and Maggie Larche ², ¹McMaster University, Mississauga, ON, Canada, ²McMaster University, Hamilton, ON, Canada
Background/Purpose: The gastrointestinal tract (GIT) is commonly involved in SSc with up to 98% of patients reporting GIT manifestations. Small intestinal bacterial overgrowth (SIBO) is…
Abstract Number: 865 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert Spiera¹, Laura Hummers ², Lorinda Chung ³, Tracy Frech ⁴, Robyn Domsic ⁵, Vivien Hsu ⁶, Daniel Furst ⁷, Jessica Gordon ¹, Madeline Myers ⁸, Robert W Simms ⁹, Elizabeth Lee ¹⁰, Scott Constantine ¹⁰, Nancy Dgetluck ¹⁰, Bradley Bloom ¹⁰ and Barbara White ¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ³Stanford, Palo Alto, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ⁷University of California, Los Angeles, CA, ⁸University of Texas, Houston, Houston, TX, ⁹Boston University, Boston, MA, ¹⁰Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models…
Abstract Number: 1067 • 2019 ACR/ARP Annual Meeting
Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis
Yiwei Yuan¹, Yue Wang ², Patricia Pioli ³ and Michael Whitfield ⁴, ¹Geisel School of Medicine at Dartmouth, Hanover, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth College, Hanover, ⁴Geisel School of Medicine at Dartmouth College, Biomedical Data Science at Dartmouth College, Hanover
Background/Purpose: Systemic sclerosis (SSc; scleroderma) is a rare, heterogenous autoimmune disease characterized by skin fibrosis, vasculopathy and internal organ involvement. SSc patients can be divided…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2590 • 2019 ACR/ARP Annual Meeting
Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis
Anita Chandrasekaran¹, Imran Omar ², Zhicheng Fu ³, Shangping Ren ³ and Monique Hinchcliff ¹, ¹Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³San Diego State University, Department of Computer Science, San Diego, CA
Background/Purpose: Calcinosis cutis, found in both systemic sclerosis (SSc) and juvenile dermatomyositis patients, can be extensive and debilitating. Potential treatments have been identified, but a…
Abstract Number: 2611 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Rossana Mejia-Romero ¹, Natalia Aguilera², Juan Pablo Alzate-Granados ³, C Escobar -Soto ⁴, Claudia Mendoza-Pinto ⁵, Mario García-Carrasco ⁵ and Adriana Rojas-Villarraga ⁶, ¹Center for Arthritis and Rehabilitation (CAYRE IPS) ,University of Barcolena, Bogotá, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogota, Distrito Capital de Bogota, Colombia, ⁴TRUSTEM, Bogotá, Distrito Capital de Bogota, Colombia, ⁵Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE CMNMAC - CIBIOR, Instituto Mexicano del Seguro Social. Department of Rheumatology and Immunology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ⁶Fundacion Universitaria de Ciencias de La Salud-FUCS. Hospital Infantil Universitario San José., Bogotá, Distrito Capital de Bogota, Colombia
Background/Purpose: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and…
Abstract Number: 2705 • 2018 ACR/ARHP Annual Meeting
Optimized Protocol for Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
Tomonori Ishii¹, Yasushi Kawaguchi², Osamu Ishikawa³, Hiromitsu Takemori⁴, Naruhiko Takasawa⁵, Hitoshi Kobayashi⁶, Yuichi Takahashi⁷, Hidekata Yasuoka⁸, Takao Kodera⁹, Osamu Takai¹⁰, Izaya Nakaya¹¹, Tomomasa Izumiyama¹², Hiroshi Fujii¹³, Yukiko Kamogawa¹³, Yuko Shirota¹³, Tsuyoshi Shirai¹³, Yoko Fujita¹⁴, shinichiro saito¹⁵, Hiroaki Shimokawa¹⁶ and Hideo Harigae¹³, ¹Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Dermatology, Gunma University Graduate School of Medicine, gunma, Japan, ⁴Aomori Prefectural Central Hospital, Aomori, Japan, ⁵Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Sendai, Japan, ⁶Iwate Medical University Hospital, Morioka, Japan, ⁷Ｙｕ　Ｆａｍｉｌｙ　Ｃlinic, Sendai, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ⁹Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ¹⁰Osaki Citizen Hospital, Sendai, Japan, ¹¹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ¹²Higashisendai Rheumatic Disease Clinic, Sendai, Japan, ¹³Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹⁴Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹⁵IMS Meirikai Sendai General Hospital, Sendai, Japan, ¹⁶Department of Cardiovascular medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Extracorporeal shock wave therapy (ESWT) at low energy has been shown to be effective for digital ulcers in systemic sclerosis (SSc) in our study…
Abstract Number: 2709 • 2018 ACR/ARHP Annual Meeting
Conversion of Normal Mean Pulmonary Arterial Pressure to Pulmonary Hypertension in Systemic Sclerosis – a Longitudinal Observational Study
Amber Young¹, Scott H. Visovatti², Tom Cascino², Nektarios Vasilottos³, Vallerie McLaughlin² and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Active screening detects PH earlier and may…
Abstract Number: 2938 • 2018 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial
Dinesh Khanna¹, Celia J. F. Lin², Helen Spotswood³, Jeffrey Siegel², Angelika Jahreis², Christopher P. Denton⁴ and Daniel E. Furst⁵, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Genentech, Inc., South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Treatment with the IL-6 receptor inhibitor tocilizumab (TCZ) in early progressive systemic sclerosis (SSc; focuSSced trial; NCT02453256) resulted in numeric improvements in skin sclerosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].